Bank Julius Baer & Co
ABUS icon

Bank Julius Baer & Co’s Arbutus Biopharma ABUS Stock Holding History

Bank Julius Baer & Co’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-7,800
Closed -$30K – 579
2021
Q4 		$30K Buy
7,800
+1,300
+20% +$5.05K ﹤0.01% 705
2021
Q3 		$28K Sell
6,500
-101
-2% -$337 ﹤0.01% 725
2021
Q2 		$20K Buy
6,601
+101
+2% +$313 ﹤0.01% 756
2021
Q1 		$22K Buy
6,500
+21
+0.3% +$81 ﹤0.01% 740
2020
Q4 		$23K Buy
6,479
+4,979
+332% +$17.4K ﹤0.01% 738
2020
Q3 		$5K Buy
+1,500
New +$4.56K ﹤0.01% 702

Other funds holding ABUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bank Julius Baer & Co's ABUS Position: Q1 2022 in Review

Bank Julius Baer & Co sold out of Arbutus Biopharma (ABUS) in Q1 2022, closing a stake of 7,800 shares — an estimated $30K sold.

Bank Julius Baer & Co first reported a position in ABUS in Q3 2020 and held it in 6 quarters. The position peaked at $30K in Q4 2021. 119 funds tracked by Wall St. Rank hold ABUS as of Q1 2022.

  • Bank Julius Baer & Co reported no remaining Arbutus Biopharma position as of Q1 2022 after selling out during the quarter.
  • Bank Julius Baer & Co sold 7,800 Arbutus Biopharma shares in Q1 2022, an estimated $30K.
  • Bank Julius Baer & Co first reported a position in Arbutus Biopharma in Q3 2020 and held it in 6 quarters.
  • Bank Julius Baer & Co's Arbutus Biopharma position peaked at $30K in Q4 2021.
  • 119 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2022.

Based on Bank Julius Baer & Co's 13F filing for Q1 2022, filed 9 May 2022.